Guizhou Bailing Group Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Guizhou Bailing Group Pharmaceutical Co., Ltd. carries a market capitalization of 6.39B, placing it among publicly traded companies globally. Its enterprise value stands at 7.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.39B |
| Enterprise Value | 7.58B |
Share Statistics
Guizhou Bailing Group Pharmaceutical Co., Ltd. currently has 1.40B shares outstanding.
| Shares Outstanding | 1.40B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Guizhou Bailing Group Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 248.60. The price-to-sales ratio is 1.99, and the price-to-book ratio stands at 2.09.
| PE Ratio | 248.60 |
| PS Ratio | 1.99 |
| PB Ratio | 2.09 |
| P/TBV Ratio | 2.20 |
| P/FCF Ratio | 97.77 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Guizhou Bailing Group Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 88.85 and an EV/FCF ratio of 84.02. The EV/Sales ratio of 2.41 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 88.85 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.41 |
| EV / EBITDA | 88.85 |
| EV / EBIT | 88.85 |
| EV / FCF | 84.02 |
Financial Position
Guizhou Bailing Group Pharmaceutical Co., Ltd. maintains a current ratio of 1.01, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.58, indicating elevated leverage, while an interest coverage ratio of 1.05 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.01 |
| Quick Ratio | 0.15 |
| Debt / Equity | 54.58 |
| Debt / EBITDA | 20.97 |
| Interest Coverage | 1.05 |
Financial Efficiency
Guizhou Bailing Group Pharmaceutical Co., Ltd. posts a return on equity of -0.06 and a return on invested capital of 0.54.
| Return on Equity (ROE) | -0.06 |
| Return on Assets (ROA) | -0.03 |
| Return on Invested Capital (ROIC) | 0.54 |
| Return on Capital Employed (ROCE) | 0.34 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.38 |
Taxes
Over the trailing twelve months, Guizhou Bailing Group Pharmaceutical Co., Ltd. has paid 10.60M in income taxes, reflecting an effective tax rate of 67.92.
| Income Tax | 10.60M |
| Effective Tax Rate | 67.92 |
Stock Price Statistics
Guizhou Bailing Group Pharmaceutical Co., Ltd.'s stock has declined approximately -16.60584% over the past 52 weeks. The 50-day moving average sits at 4.69, while the 200-day moving average is 4.98.
| Beta (5Y) | N/A |
| 52-Week Price Change | -16.60584% |
| 50-Day Moving Average | 4.69 |
| 200-Day Moving Average | 4.98 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guizhou Bailing Group Pharmaceutical Co., Ltd. generated 3.14B in revenue and converted that into -2.00M in net income, yielding earnings per share of 0.00. EBITDA reached 85.26M, while operating income came in at 85.26M.
| Revenue | 3.14B |
| Gross Profit | 1.68B |
| Operating Income | 85.26M |
| Pretax Income | 15.61M |
| Net Income | -2.00M |
| EBITDA | 85.26M |
| EBIT | 85.26M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Guizhou Bailing Group Pharmaceutical Co., Ltd. holds 491.63M in cash and equivalents against 1.79B in total debt, resulting in a net debt position of 1.17B. Total book value stands at 3.00B, with working capital of 16.91M providing operational flexibility.
| Cash & Cash Equivalents | 491.63M |
| Total Debt | 1.79B |
| Net Debt | 1.17B |
| Equity (Book Value) | 3.00B |
| Book Value Per Share | 2.48 |
| Working Capital | 16.91M |
Cash Flow
After subtracting -64.03M in capital expenditures, free cash flow totaled -64.03M - equivalent to -0.05 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -64.03M |
| Free Cash Flow | -64.03M |
| FCF Per Share | -0.05 |
Margins
Guizhou Bailing Group Pharmaceutical Co., Ltd. operates with a gross margin of 53.28, reflecting its pricing power and cost economics. The operating margin of 2.71 and net profit margin of -0.06 provide insight into operational efficiency.
| Gross Margin | 53.28 |
| Operating Margin | 2.71 |
| Pretax Margin | 0.50 |
| Profit Margin | -0.06 |
| EBITDA Margin | 2.71 |
Dividends & Yields
The company's payout ratio of 585.55 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.06 |
| Dividend Yield | N/A |
| Payout Ratio | 585.55 |
| Shareholder Yield | 2.79 |
| FCF Yield | 1.02 |
Stock Splits
Guizhou Bailing Group Pharmaceutical Co., Ltd.'s most recent stock split took place on October 20, 2015 with a 1:3 split ratio.
| Last Split Date | 10/20/2015 |
| Split Ratio | 1:3 |
Scores
Guizhou Bailing Group Pharmaceutical Co., Ltd. posts an Altman Z-Score of 1.93, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.93 |